DAKLINZA |
BMS' drug has also been given a broad label; it can be used in the four main strains of hepatitis C
(genotypes 1, 2, 3, and 4) as well as in patients with advanced liver
disease and who have failed prior treatment with HCV protease inhibitors
such as Merck & Co's Victrelis (boceprevir) and Vertex' Incivek
(telaprevir)
-------------
No comments:
Post a Comment